Business Context and Reporting Period
Aptevo Therapeutics Inc. filed a Form 8-K on December 20, 2018, reporting the entry into a Material Definitive Agreement. The Company is a Delaware corporation focused on developing next-generation ADAPTIR bispecific antibody candidates.
Key Financial Metrics and Transaction Details
This filing details a financing arrangement rather than standard periodic financial results. Key metrics include:
- Total Commitment: Lincoln Park Capital Fund, LLC ("Lincoln Park") committed to purchase up to $35.0 million of Aptevo's common stock.
- Transaction Structure: A "Regular Purchase" agreement allowing Aptevo to sell shares at its discretion over a 36-month period following the effectiveness of a registration statement.
- Share Issuance Limits:
- Standard Regular Purchase: Up to 100,000 shares per day.
- Increased Limits: Up to 125,000 shares if price $\ge$ $2.00; up to 150,000 shares if price $\ge$ $3.00; up to 200,000 shares if price $\ge$ $4.00.
- Maximum Daily Cap: $2,000,000 per Regular Purchase.
- Exchange Cap: Issuance is limited to 19.99% of outstanding shares (4,538,319 shares) unless shareholder approval is obtained or the average sale price exceeds the Base Price ($1.50).
- Commitment Shares: 105,467 shares issued immediately; an additional 195,867 shares to be issued upon registration statement effectiveness.
- Use of Proceeds: Advancement of ADAPTIR candidates, working capital, and general corporate purposes.
The filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes and Unusual Items
The primary material change is the establishment of a new equity financing facility. Unlike traditional equity offerings with fixed discounts, this agreement utilizes prevailing market prices without a fixed discount, subject to a floor price. The Company has agreed to a "no-shop" provision regarding variable rate transactions for a defined period. Lincoln Park is prohibited from short selling or hedging Aptevo's shares.
Guidance, Outlook, and Risks
Outlook: The Company expects to utilize proceeds to support its drug development pipeline. Actual sales depend on market conditions and the Company's funding needs.
Risks and Contingencies:
- Termination: The Company may terminate the agreement at any time without penalty. The agreement automatically terminates in the event of bankruptcy proceedings.
- Default: During an "event of default" (outside Lincoln Park's control), the Company cannot initiate purchases, though Lincoln Park cannot terminate.
- Ownership Limits: Sales are restricted if they would cause Lincoln Park to beneficially own more than 9.99% of the Common Stock.
- Regulatory Conditions: Sales cannot commence until the SEC declares the registration statement effective and a final prospectus is filed.
Investor Verification Checklist
- Verify the effectiveness date of the registration statement required to commence sales.
- Monitor the trading price of Aptevo's Common Stock relative to the $1.50 Base Price and the tiered thresholds ($2.00, $3.00, $4.00) to understand potential share issuance volumes.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific definitions of "floor price" and "event of default."
- Confirm the total number of shares outstanding to calculate the precise impact of the 19.99% Exchange Cap.